Amylyx Pharmaceuticals is a clinical-stage pharmaceutical company developing therapies for neurodegenerative diseases, endocrine disorders, and metabolic conditions. Its original product AMX0035 (Relyvrio) was withdrawn from the U.S. and Canadian markets after the Phase 3 PHOENIX trial failed to show benefit in ALS. The company is now advancing AMX0035 in post-bariatric hypoglycemia (Phase 3 LUMA trial) and exploring additional endocrine and neurology indications, with co-CEOs Justin Klee and Josh Cohen framing Amylyx as a multi-asset neuroscience and metabolic player.
Company Info
Upcoming Milestones & Key Dates
Topline LUMA Phase 3 readout in post-bariatric hypoglycemia
Regulatory update on AMX0035 label and indication strategy post-ALS withdrawal
Clinical Development Pipeline
Recent News
After the market withdrawal of its only approved product, Amylyx is gearing up for a pivotal Phase 3 readout in post-bariatric hypoglycemia, with co-CEO Justin Klee framing the company as a multi-asset neuroscience player.
Leadership Team
Co-Chief Executive Officer and Co-Founder
Co-Chief Executive Officer and Co-Founder
Careers & Job Openings